axogen logo.jpg
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
March 05, 2024 07:00 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
axogen logo.jpg
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
February 13, 2024 16:30 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2024 16:15 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
January 18, 2024 17:00 ET | Axogen, Inc.
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve...
axogen logo.jpg
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
January 04, 2024 16:45 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
January 04, 2024 16:40 ET | Axogen, Inc.
ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today...
axogen logo.jpg
Axogen Announces Promotions on Research and Development Team
January 04, 2024 16:35 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) --  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
axogen logo.jpg
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
December 26, 2023 16:15 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Axogen Announces Transition of Finance Team Leadership
December 06, 2023 07:00 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
axogen logo.jpg
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023 17:00 ET | Axogen, Inc.
ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today...